NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals is an Australian biopharmaceutical company founded in 2016, dedicated to developing innovative peptide-based pharmaceutical products to address unmet medical needs in neurodegenerative conditions. Their lead compound, EmtinB, aims to slow down cell death and regenerate damaged nerves and tissue fibers, targeting therapeutic indications such as Alzheimer’s Disease, Multiple Sclerosis, Glaucoma, and Post-Covid Lung Fibrosis. The company's commitment to a methodically planned, efficiently executed, and risk-aware research and development program underlines their strategic approach. With a focus on the Biopharma, Biotechnology, and Pharmaceutical industries, NeuroScientific Biopharmaceuticals operates from its headquarters in Australia. The firm is seeking investment, making it an intriguing prospect for venture capitalists aiming to support groundbreaking therapies in the biopharmaceutical space. For more information, visit www.neuroscientific.com.